文献速递胸部肿瘤放疗

早期非小细胞肺癌根治性立体定向消融放疗后孤立性淋巴结复发

Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiation Therapy for Non-Small Cell Lung Cancer.
PubMed 文献 · Pract Radiat Oncol · 2022-07-17

该回顾性队列研究纳入2003至2018年接受根治性立体定向消融放疗的342例T1-3N0M0非小细胞肺癌患者,中位随访3.3年,3年孤立性淋巴结复发率为10.6%。34例复发患者中,接受同步放化疗者生存结局最佳,3年总生存率和无进展生存率分别为81.5%和63.9%。

要点

  • 接受根治性立体定向消融放疗的早期非小细胞肺癌患者3年孤立性淋巴结复发率为10.6%(95%CI 6.6%-13.4%)。
  • 34例孤立性淋巴结复发患者中,同步放化疗组3年总生存率为81.5%(61.1%-100.0%),无进展生存率为63.9%(40.7%-100.0%)。
  • 接受挽救性放疗或同步放化疗的患者中,14.3%出现3级毒性反应,无4级及以上毒性反应。

核心结论

  • 在接受立体定向消融放疗的早期非小细胞肺癌患者中,约10%出现孤立性淋巴结复发。
  • 孤立性淋巴结复发患者中,接受挽救性同步放化疗者总生存率和无进展生存率最高。

研究设计与样本

  • 回顾性队列研究,纳入2003至2018年接受根治性立体定向消融放疗的342例T1-3N0M0非小细胞肺癌患者。
  • 评估孤立性淋巴结复发发生率及基线因素,并对复发患者描述治疗模式及生存结局。

主要发现

  • 中位随访3.3年,3年孤立性淋巴结复发率为10.6%(95%CI 6.6%-13.4%)。
  • 34例孤立性淋巴结复发患者中,3年总生存率为39.3%(24.4%-63.3%),3年无进展生存率为26.7%(14.1%-0.3%)。
  • 34例复发患者接受单纯放疗者占26.7%,同步放化疗者占43.3%,单纯化疗者占13.3%,观察者占16.7%。
  • 接受同步放化疗的患者3年总生存率为81.5%(61.1%-100.0%),3年无进展生存率为63.9%(40.7%-100.0%)。
  • 接受挽救性放疗或同步放化疗的患者中,14.3%出现3级毒性反应,无4级及以上毒性反应。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Stereotactic ablative radiation therapy (SABR) results in high rates of primary tumor control for early-stage non-small cell lung cancer (NSCLC). For patients with isolated hilar or mediastinal nodal recurrence (INR) after SABR, the optimal salvage treatment strategy is unclear. The purpose of this study was to determine the rate of INR after SABR for early-stage NSCLC and to describe patterns of care and treatment outcomes after salvage therapy. METHODS AND MATERIALS: This retrospective cohort study included 342 patients with stage T1-3N0M0 NSCLC treated with definitive SABR from 2003 to 2018. We evaluated the incidence of INR and baseline factors between patients who did and did not experience INR. Among patients who experienced INR, we described treatment patterns and outcomes including overall survival (OS) and progression free survival (PFS) from the time of nodal failure using the Kaplan-Meier method. RESULTS: With a median follow-up of 3.3 years, the 3-year INR rate was 10.6% (95% CI, 6.6%-13.4%). Among the 34 patients experiencing INR, the 3-year rates of OS and PFS were 39.3% (24.4%-63.3%) and 26.7% (14.1%-0.3%), respectively. The 34 patients with INR were treated with radiation therapy alone (26.7%), concurrent chemoradiation therapy (43.3%), chemotherapy alone (13.3%), or observation (16.7%). Patients treated with concurrent chemoradiation therapy had the best survival outcomes, with a 3-year OS and PFS of 81.5% (61.1%-100.0%) and 63.9% (40.7%-100.0%), respectively. Of the patients treated with salvage radiation therapy or concurrent chemoradiation therapy, 14.3% experienced grade 3 toxic effects, and no patients had grade ≥4 toxic effects. CONCLUSIONS: In this study, INR occurred in approximately 10% of patients treated with SABR for early-stage NSCLC. The highest rates of OS and PFS among patients with INR were observed in those treated with salvage chemoradiation therapy.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Devine M, Merriott DJ, No HJ, et al. Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiation Therapy for Non-Small Cell Lung Cancer. Pract Radiat Oncol. 2022. PMID: 35858658. doi:10.1016/j.prro.2022.06.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。